Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Receivables: 2021-2025

  • Nurix Therapeutics' Receivables was N/A to $20.7 million in Q2 2025 from the same period last year, while for May 2025 it was $43.6 million, marking a year-over-year change of. This contributed to the annual value of $6.9 million for FY2021, which is N/A change from last year.
  • Per Nurix Therapeutics' latest filing, its Receivables stood at $20.7 million for Q2 2025, which was up 158.75% from $8.0 million recorded in Q3 2023.
  • In the past 5 years, Nurix Therapeutics' Receivables ranged from a high of $20.7 million in Q2 2025 and a low of $2.5 million during Q2 2021.
  • Moreover, its 2-year median value for Receivables was $14.3 million (2023), whereas its average is $14.3 million.